MTOR and central nervous system cancer: (Table 2, Table 3 and Table 4) These results are consistent with previous studies that have demonstrated a predominance in the PI3K/Akt/mTOR and Ras/BRAF/Mek/Erk protein kinase pathways in molecularly targeted glioma treatment [5,6].